When will Compass Pathways submit a NDA for COMP360 psilocybin? (COMP360 psilocybin - NDA)
98%before December
- before December98%▲ 6
- before 202798%▲ 5
- before April 202798%
Install
FDA decision: Ulixacaltamide by Praxis Precision Medicines (on or before January 29, 2027)
The odds
73%chance▲ 1
How the odds have moved
Yes: 73% on Nov 3, 73% now.
Each outcome's chance over time on Kalshi. The dots along the bottom are headlines about its subject: point at one to read it.
Every outcome
| Outcome | Chance | Day | Bid | Ask | Pays | Contracts |
|---|---|---|---|---|---|---|
| Yes | 73% | ▲ 1 | 69¢ | 76¢ | $1.32 |
"Pays" is what a $1 stake returns if that outcome happens, at the price shown (before any fees). Bid and ask are the best prices to sell and buy "Yes".
The news: FDA, Praxis Precision Medicines, Ulixacaltamide
Search ›- Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on November 2, 2026…
- Analysts Have Conflicting Sentiments on These Healthcare Companies: Capricor Therapeutics (CAPR), Minerva Neurosciences (NERV) and Bio-Techne (TECH)Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Capricor Therapeutics (CAPR), Minerva Neurosciences (NERV) and Bio-Techne (TECH). Capricor Therapeutics received a Buy rating and a $28.00…
- (PRAX) Movement Within Algorithmic Entry FrameworksStock Traders Daily Key findings for Praxis Precision Medicines Inc. (NASDAQ: PRAX) - Near-Term Neutral Sentiment Suggests a Stall Amid Mid and Long-Term Strength - Exceptional 75.7:1 risk-reward setup targets 21.9% gain vs 0.3% risk…
- FDA grants tentative approval to low-cost HIV shotThe potential rollout of a more affordable injection to help prevent HIV infection lifts hopes for reduced AIDS deaths in Africa. US regulatorsâ approval of a cheaper HIV shot has lifted hopes in some of the worldâs poorest countries…
- FDA probes tumour risk tied to Novartis gene therapyTradingView FDA probes tumour risk tied to Novartis gene therapy
- Novartis Gene Therapy Under FDA ScrutinyReuters The US Food and Drug Administration said on Friday it was investigating a risk... The US Food and Drug Administration said on Friday it was investigating a risk of neoplasia, or tumour formation including malignancy, associated…
- FDA Upgrades Recall of Gelatelli-Brand GelatoThe lot of Gelatelli coffee and vanilla gelato that was withdrawn from the market last month was flagged by the U.S. Food and Drug Administration (FDA) as a Class I recall event this week. Concerns about the potential for Listeria…
- Hutchmed China's sovleplenib designated orphan drug by FDAHutchmed China Ltd - Hong Kong-based biopharmaceutical company - Says its autoimmune hemolytic anemia medication sovleplenib was granted orphan drug designation by the US Food & Drug Administration.... Hutchmed China Ltd - Hong Kong-based…
- FDA Investigates Cancer Risk Associated With Novartis' Zolgensma Gene TherapyIn medicine, one truth transcends time: a drug's worth is measured not merely by how effectively it fights disease, but also by how safely it does so. One medicine that has recently drawn the FDA's attention over emerging safety concerns…
- Maharashtra FDA Declares Wellness Capsules Spurious After Detecting Undisclosed Erectile Dysfunction DrugMumbai, November 7, 2026: A capsule marketed as Urja Urbpro has been declared spurious after laboratory tests detected tadalafil, a prescription drug commonly used to treat erectile dysfunction, in the product without it being declared as…
- FDA Approves Amivantamab for Recurrent or Metastatic HNSCCFDA grants accelerated approval to amivantamab and hyaluronidase-lpuj for recurrent or metastatic head and neck squamous cell carcinoma. The approval was based on cohort 1 of the open-label, multicenter phase 1b/2 OrigAMI-4 trial, which…
- FlowStop Hemostatic Spray Hits 18,000 Units, Seeks FDA ClearanceSouth Korean maker INNOPHARMA designs the no-compression liquid spray for bystanders, firefighters and soldiers who reach injuries before medical care DAEGU, South Korea, Nov. 6, 2026 /PRNewswire/ -- A liquid spray lets people without…
Related markets
All fda & drugs ›Will the FDA approve retatrutide? (retatrutide (LY3437943))
Dec 9, 2027even chance by
- Before Jan 1, 20272%
- Before Jul 1, 202712%▼ 9
- Before Jan 1, 202856%
2 more
- Before Jul 1, 202885%
- Before Jan 1, 202990%
Will the FDA approve any psychedelic substance for medical use this year? (Before 2027)
16%chance▼ 1
When will the FDA reclassify BPC-157 to Category 1?
10%Before 2027
- Before 202710%▲ 1
When will the FDA approve Compass Pathways' COMP360 Psilocybin? (COMP360 Psilocybin for Treatment-Resistant Depression)
90%Before 2028
- Before 202890%▼ 1
- Before October 202788%▼ 1
- Before July 202787%
2 more
- Before Mar 1, 202765%▼ 1
- Before Jan 1, 202719%▲ 2
FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
74%chance▼ 1
Odds are traders' prices on Kalshi, Polymarket, ForecastEx and Crypto.com, not forecasts by 4Progressives. Prices read from the venues just now. Prices may be delayed. Money traded on Kalshi and ForecastEx is estimated from contracts. Not betting or investment advice.
Prediction-market prices are what traders pay for each outcome on Kalshi, Polymarket, ForecastEx and Crypto.com, read as the market's implied chance. They are not forecasts by 4Progressives, can move fast and can be wrong; they are read every few minutes and may be delayed. Money traded on Kalshi and ForecastEx is estimated from contracts at their price. News comes from the 4Progressives index; prices of stocks, rates and coins from 4Progressives Finance. Nothing here is betting, financial or investment advice. Terms of use. How to use Predictions